Effect of pravastatin and fosinopril on recurrent urinary tract infections

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 708-714

  Pouwels, Koen B ^a   Visser, Sipke T ^a   Hak, Eelko ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Bacterial invasion; Cystitis; Statin

Indexed keywords

CREATININE; FOSINOPRIL; PLACEBO; PRAVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FACTORIAL DESIGN; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION;

ADULT; AGED; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; DRUG PRESCRIPTIONS; FEMALE; FOSINOPRIL; HUMANS; MALE; MIDDLE AGED; NITROFURANS; PRAVASTATIN; RECURRENCE; URINARY TRACT INFECTIONS;

EID: 84873583501     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks419     Document Type: Article

References (43)

1. van Pinxteren B, van Vliet SM, Wiersma TJ et al. Summary of the practice guideline 'urinary-tract infections' (second revision) from the Dutch college of general practitioners. Ned Tijdschr Geneeskd 2006; 150: 718-22.
2. Hunstad DA, Justice SS. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli. Annu Rev Microbiol 2010; 64: 203-21.
3. Lipsky BA. Urinary tract infections in men: epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med 1989; 110: 138-50.
4. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 2001; 69: 4572-9.
5. Schilling JD, Mulvey MA, Vincent CD et al. Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism. J Immunol 2001; 166: 1148-55.
6. Duncan MJ, Li G, Shin JS et al. Bacterial penetration of bladder epithelium through lipid rafts. J Biol Chem 2004; 279: 18944-51.
7. Martinez JJ, Hultgren SJ. Requirement of rho-family GTPases in the invasion of type 1-piliated uropathogenic Escherichia coli. Cell Microbiol 2002; 4: 19-28.
8. Song J, Bishop BL, Li G et al. TLR4-initiated and cAMP-mediated abrogation of bacterial invasion of the bladder. Cell Host Microbe 2007; 1: 287-98.
9. Burnham CA, Shokoples SE, Tyrrell GJ. Rac1, RhoA, and Cdc42 participate in HeLa cell invasion by group B Streptococcus. FEMS Microbiol Lett 2007; 272: 8-14.
10. Cordle A, Koenigsknecht-Talboo J, Wilkinson B et al. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 2005; 280: 34202-9.
11. Rashid M, Tawara S, Fukumoto Y et al. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 2009; 73: 361-70.
12. Dechend R, Gieffers J, Dietz R et al. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation 2003; 108: 261-5.
13. Antoniades C, Bakogiannis C, Tousoulis D et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010; 122: S66-73.
14. Maack C, Kartes T, Kilter H et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003; 108: 1567-74.
15. Zaas DW, Duncan M, Rae Wright J et al. The role of lipid rafts in the pathogenesis of bacterial infections. Biochim Biophys Acta 2005; 1746: 305-13.
16. Horn MP, Knecht SM, Rushing FL et al. Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J Pharmacol Exp Ther 2008; 326: 135-43.
17. Rosch JW, Boyd AR, Hinojosa E et al. Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J Clin Invest 2010; 120: 627-35.
18. Fleming DM, Verlander NQ, Elliot AJ et al. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol Infect 2010; 138: 1281-8.
19. Smeeth L, Douglas I, Hall AJ et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009; 67: 99-109.
20. Diercks GF, Janssen WM, van Boven AJ et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol 2000; 86: 635-8.
21. Asselbergs FW, Diercks GF, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-16.
22. Pharmacy-dispensing Database of IADB.nl. http://www.iadb.nl (2 October 2012, date last accessed).
23. Tobi H, van den Berg P, de Jong-van den Berg L. The InterAction database: synergy of science and practice in pharmacy. Lect Notes Comput Sci 2000; 1933: 93-108.
24. Akkerman AE, Kuyvenhoven MM, Verheij TJ et al. Antibiotics in Dutch general practice: nationwide electronic GP database and national reimbursement rates. Pharmacoepidemiol Drug Saf 2008; 17: 378-83.
25. Ong DS, Kuyvenhoven MM, van Dijk L et al. Antibiotics for respiratory, ear and urinary tract disorders and consistency among GPs. J Antimicrob Chemother 2008; 62: 587-92.
26. Russo TA, Stapleton A, Wenderoth S et al. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. J Infect Dis 1995; 172: 440-5.
27. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 1990; 80: 331-3.
28. Juhlin T, Bjorkman S, Hoglund P. Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors. Eur J Heart Fail 2005; 7: 1049-56.
29. Marshall SW. Power for tests of interaction: effect of raising the type I error rate. Epidemiol Perspect Innov 2007; 4: 4.
30. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992; 3: 452-6.
31. Rosen DA, Hooton TM, Stamm WE et al. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 2007; 4: e329.
32. Gulati S, Kher V, Arora P et al. Urinary tract infection in nephrotic syndrome. Pediatr Infect Dis J 1996; 15: 237-40.
33. Pedersen G, Schonheyder HC, Sorensen HT. Source of infection and other factors associated with case fatality in community-acquired bacteremia-a Danish population-based cohort study from 1992 to 1997. Clin Microbiol Infect 2003; 9: 793-802.
34. Elhanan G, Sarhat M, Raz R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-acquired bacteraemia due to urinary tract infection. J Infect 1997; 35: 283-8.
35. Second Dutch National Survey of General Practice. www.nivel.nl/pdf/ ns2_r0_h14.pdf (2 October 2012, date last accessed).
36. Pechlivanoglou P, van der Veen WJ, Bos JH et al. Analyzing generic and branded substitution patterns in the Netherlands using prescription data. BMC Health Serv Res 2011; 11: 89.
37. Verhave JC, Gansevoort RT, Hillege HL et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl 2004; 92: S18-21.
38. Funfstuck R, Ott U, Naber KG. The interaction of urinary tract infection and renal insufficiency. Int J Antimicrob Agents 2006; 28 Suppl 1: S72-7.
39. Gilbert DN. Urinary tract infections in patients with chronic renal insufficiency. Clin J Am Soc Nephrol 2006; 1: 327-31.
40. Yamasaki T, Naganuma T, Iguchi T et al. Association between chronic kidney disease and small residual urine volumes in patients with benign prostatic hyperplasia. Nephrology (Carlton) 2011; 16: 335-9.
41. Beetz R. Mild dehydration: a risk factor of urinary tract infection? Eur J Clin Nutr 2003; 57 Suppl 2: S52-8.
42. Navis G, Faber HJ, de Zeeuw D et al. ACE inhibitors and the kidney. A risk-benefit assessment. Drug Saf 1996; 15: 200-11.
43. Whelton A, Schulman G, Wallemark C et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 1465-70.